FDA approves new combination treatment for hepatitis C. Food and Drug Administration.
Baker
R
R
D000998:Antiviral Agents / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D017277:Drug Approval; D004338:Drug Combinations; D006526:Hepatitis C / Q000188:drug therapy*; D006801:Humans; D007370:Interferon Type I / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D011994:Recombinant Proteins; D012254:Ribavirin / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration
D000998:Antiviral Agents; D004338:Drug Combinations; D007370:Interferon Type I; D011994:Recombinant Proteins; D012254:Ribavirin